JAGXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Jaguar Health, Inc. hold a median 12-month price target of $263 — +30117.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 21 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Jaguar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JAGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +30117.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2025 | First Berlin | Initiates | Buy | $60 |
| 7 July 2021 | Cantor Fitzgerald | Initiates | Overweight | $5.00 |
| 25 Nov 2020 | Aegis Capital | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 25 Nov 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 25 Nov 2020 | Rodman & Renshaw | Initiates | Buy | — |
| 18 Nov 2019 | H.C. Wainwright | Reiterates | Buy | — |
| 18 Nov 2019 | HC Wainwright & Co. | Reiterates | Buy | $10 → $3.00 |
| 12 Sept 2019 | Ladenburg Thalmann | Initiates | Buy | — |
| 11 July 2017 | Rodman & Renshaw | Initiates | Buy | — |
| 12 Nov 2015 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JAGX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 95% of US stocks
Cheaper than 93% of US stocks
Cheaper than 69% of US stocks
Higher than 99% of US stocks
Higher than 97% of US stocks
Higher than 98% of US stocks
Higher than 96% of US stocks
Higher than 5% of US stocks
Higher than 99% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Jaguar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the prepared remarks transcript from Jaguar Health's Q2 2026 earnings call. The item consists of the company's prepared remarks for that quarterly earnings discussion.
Why it matters — A JAGX watcher would care because the transcript provides the company's own commentary on its second-quarter 2026 performance and outlook.
Jaguar Health reported its consolidated second-quarter 2026 financial results. The company highlighted its global development program for crofelemer for rare intestinal failure diseases, including results presented at ESPGHAN 2026 showing reduction of parenteral support normalized to body weight of up to 48% in a patient with microvillus inclusion disease. Jaguar expects the clinical package for an NDA for MVID to be ready by end of 2026, with NDA submission planned for Q2 2027, and will host an investor webcast on August 19, 2026.
Why it matters — A JAGX watcher would care because progress on the crofelemer MVID development program provides a concrete regulatory timeline toward a potential NDA submission in Q2 2027.
Jaguar Health announced it will hold an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ended June 30, 2026 on that same date.
Why it matters — A JAGX watcher would care because the webcast will present the company's second-quarter 2026 financial results and corporate updates directly from management.
Jaguar Health announced it has satisfied conditions to receive a non-dilutive $2 million holdback payment from Future Pak related to a U.S. commercial licensing agreement for Mytesi and Canalevia-CA1, after receiving a $16 million upfront payment in January 2026.
Why it matters — This additional $2 million in non-dilutive capital supports Jaguar's strategy of funding crofelemer development for rare-disease intestinal failure indications without diluting existing shareholders.
Jaguar Health announced positive findings from exploratory surveys of dog owners and veterinary oncologists supporting the commercial opportunity for Neonorm Dog, a new plant-based, non-prescription product designed to support normal stool consistency and GI fluid balance in dogs. The company expects to make Neonorm Dog available through Amazon and Chewy, extending its existing Neonorm franchise beyond foals and calves into the companion animal market.
Why it matters — JAGX watchers would care because positive market research signals potential commercial validation for Neonorm Dog, which expands Jaguar's product line into the large companion-animal market via major retailers Amazon and Chewy.
The 1 Wall Street analysts covering Jaguar Health, Inc. have a median 12-month price target of $263, with estimates ranging from $263 to $263. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Jaguar Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jaguar Health, Inc. 57 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Jaguar Health, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +30117.6% from the last close, and Ticker Nerd's factor model ranks Jaguar Health, Inc. 57 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Jaguar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $263 to $263 over the next 12 months.
Jaguar Health, Inc. returned -98.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company specializing in plant-based prescription medicines for gastrointestinal distress in people and animals.
The most recent item we track (Seeking Alpha, 20 Aug 2026): "Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript". Seeking Alpha published the prepared remarks transcript from Jaguar Health's Q2 2026 earnings call. The item consists of the company's prepared remarks for that quarterly earnings discussion.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company specializing in plant-based prescription medicines for gastrointestinal distress in people and animals. It operates through two primary segments: Animal Health and Human Health, developing and commercializing products for companion animals, production animals, and humans. Key offerings include Mytesi, an anti-secretory antidiarrheal drug for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, a prescription product for chemotherapy-induced diarrhea in dogs. The company is advancing Crofelemer in Phase III trials for prophylaxis of diarrhea in adult cancer patients, as well as Phase II trials for conditions like short bowel syndrome, microvillus inclusion disease, diarrhea-predominant irritable bowel syndrome, and idiopathic diarrhea. Additionally, Mytesi is in Phase III for cancer therapy-related diarrhea and Phase II for irritable bowel syndrome, while NP-300, a second-generation antidiarrheal, is in Phase I for moderate-to-severe diarrhea. Headquartered in San Francisco, California, Jaguar Health, Inc. plays a focused role in addressing unmet needs in gastrointestinal health across human and veterinary markets.
CEO Ms. Lisa A. Conte · 47 employees · United States · https://jaguar.health